Brief: Active Biotech Announces New Direction

Active Biotech AB publ

05/02/2020 08:08

Feb 5 (Reuters) - Active Biotech AB  ACTI.ST :
    * ACTIVE BIOTECH ANNOUNCES NEW DIRECTION
    * BOARD OF DIRECTORS, HAS APPROVED A NEW DIRECTION FOR
COMPANY
    * THIS DECISION FOLLOWS A DETAILED OPPORTUNITY ANALYSIS OF
COMPANY'S WHOLLY OWNED CLINICAL LEAD ASSETS, LAQUINIMOD AND
TASQUINIMOD
    * GOING FORWARD, ACTIVE BIOTECH HAS A PROJECT PORTFOLIO
COMPRISING
NAPTUMOMAB, PARTNERED TO NEOTX AND CURRENTLY IN PHASE 1B/2 FOR
TREATMENT OF ADVANCED SOLID TUMORS, AND NEW CLINICAL AND
PRE-CLINICAL PROGRAMS FOR TASQUINIMOD AND LAQUINIMOD
    * PARTIES ARE PREPARING TO INITIATE A PHASE 1B/2A STUDY IN
Q2-2020
AND EXPECT FIRST PATIENT TREATED IN Q3-2020
    * AT YEAR-END 2019 AVAILABLE CASH IS SCHEDULED TO FINANCE
ONGOING
ACTIVITIES IN NEW DIRECTION THROUGH 2021
    * CO IS EVALUATING CORPORATE DEVELOPMENT OPPORTUNITIES TO
BROADEN
SHAREHOLDER BASE, AND TO STRENGTHEN PROJECT PORTFOLIO

Source text for Eikon:  ID:nGNX3Zljc8 
Further company coverage:  ACTI.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))